International Journal of Hematology

, Volume 78, Issue 5, pp 467–474 | Cite as

Clinical Evaluation of a Recombinant Factor VIII Preparation (Kogenate) in Previously Untreated Patients with Hemophilia A

  • A. Yoshioka
  • K. Fukutake
  • J. Takamatsu
  • A. Shirahata
  • Kogenate Post-Marketing Surveillance Study Group
Case Report


The safety and efficacy of a recombinant factor VIII (rFVIII) preparation (Kogenate) for the treatment of bleeding episodes was studied in previously untreated patients (PUPs) with severe, moderate, and mild hemophilia A. Patient peripheral blood samples taken at baseline and at 3, 6, 9, 12,18, and 24 months after the first infusion were evaluated for FVIII inhibitor antibodies by the Bethesda assay, for antibodies formed against trace proteins derived from the rFVIII production process, and for general changes in laboratory test results. Samples for general laboratory testing were also drawn every 6 months after the first 24 months. Hemostatic efficacy was assessed by physicians, and adverse events were recorded throughout the study period. Forty-three PUPs (30 with FVIII:C <1%; 10 with FVIII:C 1%-5%; and 3 with FVIII:C >5%) aged 3 months to 32 years were enrolled at 33 centers in Japan. Patients were studied for a mean of 51 months (range, 11-80 months), and the mean exposure time was 83 days (range, 2-571 days). The incidence of occurrence of FVIII inhibitors was 34.9% (high responders [≥10 Bethesda U/mL], 11.6%; low responders [0.5->10 Bethesda U/mL],23.3%). The median cumulative exposure time of inhibitor detection was 12 days, indicating inhibitor development at an early stage after the start of infusion of this preparation. Hemostasis was achieved with a single dose of Kogenate in 94.8% of the 951 bleeding episodes recorded in the study. Transient increases in antibodies against baby hamster kidney proteins and antimouse immunoglobulin G were observed in 14.0% and 18.6% of patients, respectively. Anti-rFVIII seroconversion was observed in 18.6% of patients and only in patients with inhibitor antibodies. Antibody responses to trace proteins were not correlated with drug-related adverse events with the exception of FVIII activity inhibition in PUPs with anti-rFVIII seroconversion. These data indicate that Kogenate is safe and effective for the treatment of bleeding in PUPs with hemophilia A.

Key words

Recombinant factor VIII Kogenate Clinical study Previously untreated patients with hemophilia A Inhibitor Antibody to foreign protein 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene.Nature. 1984;312:326–330.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones.Nature. 1984;312:330–337.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A: Recombinant Factor VIII Study Group.N Engl J Med. 1990;323:1800–1805.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Yoshioka A. Advances in hemophilia and other coagulation disorders: recombinant factor VIII preparations.Int J Pediatr Hematol Oncol. 1994;1:491–497.Google Scholar
  5. 5.
    Fukui H, Yoshioka A, Shima M, et al. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.Int J Hematol. 1991;54:419–427.PubMedGoogle Scholar
  6. 6.
    Fukui H, Mori K, Ishikawa M, et al. A long-term, multi-center clinical study of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A [in Japanese].Nihon Yuketsu Gakkai Zasshi. 1991;37:593–604.Google Scholar
  7. 7.
    Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors [letter].Thromb Diath Haemorrh. 1975;34:869–872.Google Scholar
  8. 8.
    Shima M, Sawamoto Y, Nakai H, et al. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII: Kogenate Japanese Clinical Study Group.Int J Hematol. 1995;62:35–43.CrossRefPubMedGoogle Scholar
  9. 9.
    McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII inhibitors in patients with hemophilia A: a national cooperative study, II: observations on the initial development of factor VIII:C inhibitors.Blood. 1988;71:344–348.PubMedGoogle Scholar
  10. 10.
    Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France: French Hemophilia Study Group.Thromb Haemost. 1992;67:600–602.PubMedCrossRefGoogle Scholar
  11. 11.
    Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al. A sudden increase in factor VIII inhibitor development in multitrans- fused hemophilia A patients in the Netherlands: Dutch Hemophilia Study Group.Blood. 1993;81:2180–2186.PubMedGoogle Scholar
  12. 12.
    Schwarzinger I, Pabinger I, Korninger C, et al. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates.Am J Hematol. 1987;24:241–245.CrossRefPubMedGoogle Scholar
  13. 13.
    Colvin BT, Hay CRM, Hill FGH, Preston FE. The incidence of factor VIII inhibitors in the United Kingdom, 1990-93: Inhibitor Working Party. United Kingdom Haemophilia Centre Directors Organization.Br J Haematol. 1995;89:908–910.CrossRefPubMedGoogle Scholar
  14. 14.
    Shima M. Mechanism of the inhibitor development and management in patients with hemophilia [in Japanese].Nihon Shouni Ketsueki Gakkai Zasshi. 1999;13:399–409.Google Scholar
  15. 15.
    Abe T, Igata A, Ikematsu S, et al. Multcenter clinical effect of heat- treated factor VIII (CP-8) preparation for patients with hemophilia A [in Japanese].Rinshio to Kenkyu. 1985;62:3640–3659.Google Scholar
  16. 16.
    Fujimaki M, Tanaka A, Fukutake K, et al. Clinical evaluation of recombinant factor VIII (BL-160) in patients with hemophilia A [in Japanese].Nihon Kessen Shiketsu Gakkaishi. 1993;4:179–188.CrossRefGoogle Scholar
  17. 17.
    Fujimaki M, Goto M, Miyazaki T, et al. Clinical study of FVIII concentrate highly purified by monoclonal antibodies to FVIII(RCG- 11) [in Japanese].Kiso to Rinsho. 1992;26:299–319.Google Scholar
  18. 18.
    Shima M. Hemophilia [in Japanese].Rinshoui. 2001;27:801–806.Google Scholar
  19. 19.
    Scharrer I, Bray GL, Neutzing O. Incidence of inhibitors in haemophilia A patients: a review of recent studies of recombinant and plasma-derived factor VIII concentrates.Haemophilia. 1999;5:145–154.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lusher JM, Arkin S, Hurst D. Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: update of safety, efficacy, and inhibitor development after seven study years.Thromb Haemost. 1997;77(suppl):162–163.Google Scholar
  21. 21.
    Gruppo R, Bray GL, Schroth P, Perry M, Gemperts ED. Safety and immunogenicity of recombinant factor VIII (RecombinateTM) in previously untreated patients (PUPs): a 6.5 year update.Thromb Haemost. 1997;77(suppl):162.Google Scholar
  22. 22.
    Addigo JE, Gomperts E. Jr, Liu SL, et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.Thromb Haemost. 1992;67:19–27.CrossRefGoogle Scholar
  23. 23.
    Lusher JM. Viral safety and inhibitor development associated with monoclonal antibody-purified FVIIIC.Ann Hematol. 1991;63:138–141.CrossRefGoogle Scholar
  24. 24.
    Ingerslev J, Christiansen K, Ravn HB, Bray GL, Gomperts ED. Antibodies to heterologous proteins in hemophilia A patients receiving recombinant factor VIII (Recombinate).Thromb Haemost. 2002;87: 626–634.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2003

Authors and Affiliations

  • A. Yoshioka
    • 1
  • K. Fukutake
    • 2
  • J. Takamatsu
    • 3
  • A. Shirahata
    • 4
  • Kogenate Post-Marketing Surveillance Study Group
  1. 1.Department of PediatricsNara Medical UniversityNaraJapan
  2. 2.Department of Clinical Laboratory MedicineTokyo Medical CollegeTokyo
  3. 3.Department of Blood Transfusion, Internal Medicine INagoya University School of MedicineNagoya
  4. 4.Department of PediatricsUniversity of Occupational and Environmental HealthKitakyushuJapan

Personalised recommendations